RAC-alpha serine/threonine-protein kinase

BT-AP06158

Rabbit

IgG

20ul,50ul,100ul

Polyclonal

The antiserum was produced against synthesized peptide derived from human Akt around the phosphorylation site of Ser129. AA range:95-144

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

1 mg/ml

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

-20°C for 1 year

The serine-threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery. Mutations in this gene have been associated with the Proteus syndrome. Multiple alternatively spliced transcript variants have been found for this gene.

Human: P31749; Mouse: P31750; Rat: P47196;

55686

Human: 207; Mouse: 11651; Rat: 24185

RAC-alpha serine/threonine-protein kinase; AKT1; PKB; RAC; RAC-alpha serine/threonine-protein kinase; Protein kinase B; PKB; Protein kinase B alpha; PKB alpha; Proto-oncogene c-Akt; RAC-PK-alpha

Cancer; Epigenetics and nuclear signaling; Metabolism; Signal transduction; Neuroscience

AKT1